Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.

Back to Top

President's Message

Manabu Ikeda, MD, PhD
President (2021-2023)

As president of the IPA, this is the last time I will be delivering the president’s address, and I sincerely thank everyone for their cooperation and support over the past 2 years. I would especially like to thank Dr. Tzung-Jeng Hwang, editor-in-chief of the IPA Bulletin, who is stepping down at the same time. During the first half of my term, the novel coronavirus was still prevalent, and I was unable to meet members in person. However, in June of this year, we were able to hold the IPA congress in Lisbon in person for the first time in five years. It included over six hundred participants and was a wonderful memory. Under the new leadership of our next president Anne Margriet, preparations are steadily progressing for the Buenos Aires meeting in September 2024 and the Kanazawa (Japan) congress in September 2025.

Due to the COVID-19 pandemic and various international conflicts, the role of IPA in protecting the mental health of older adults with associated vulnerabilities is becoming even more important. The development of treatments for neurocognitive disorders, like agitation treatments for Alzheimer's disease and disease-modifying drugs, is progressing along with exciting research and development in the area of artificial intelligence, in which IPA is expected to play a leading role.

I look forward to continuing to carry out great activities with all IPA friends in 2025, and I wish you a peaceful end of the year and a bright new year!

Thank you for your dedication to supporting IPA.

With Kindest Regards.

Dr. Manabu Ikeda


Acadia Pharmaceuticals Avanir Pharmaceuticals Cambridge University Press